Alectinib D5

Alectinib D5 is a deuterated form of Alectinib, which is a highly selective small molecule inhibitor of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase. This drug is used to treat patients with non-small cell lung cancer (NSCLC) that is ALK-positive. It is also used in the treatment of ALK-positive metastatic NSCLC that is resistant or intolerant to crizotinib, another ALK inhibitor. Chemically, Alectinib D5 is a white to yellowish powder with a molecular weight of 503.71. It is stable under normal conditions and has a melting point of 120-130°C. This drug is soluble in DMSO and slightly soluble in water. The recommended dose of Alectinib D5 is 600 mg orally twice daily, with or without food. It should be taken at the same time every day to maintain a consistent level in the body. The duration of treatment depends on the patient's response and tolerability. Alectinib D5 works by inhibiting the activity of the ALK protein, which is involved in cell growth and proliferation in tumors. By blocking this protein, Alectinib D5 can slow down or stop the growth of cancer cells, leading to shrinkage of the tumor. Like any other medication, Alectinib D5 has some potential side effects, including constipation, fatigue, muscle pain, and vision problems. Patients should discuss any concerns with their healthcare provider before taking this drug.